Regulatory effects of interferon-β on osteopontin and interleukin-17 expression in multiple sclerosis.
Multiple sclerosis (MS) is a demyelinating disease characterized by autoimmune inflammation in the central nervous system. Despite over a decade of use of interferon-&#x03B2; (IFN-&#x03B2;) in the treatment of MS, its mechanisms of action are still not fully elucidated. New data now demonstrate that the 2 important proinflammatory cytokines involved in the pathogenesis of MS, osteopontin (OPN) and interleukin-17 (IL-17), are regulated by IFN-&#x03B2;. This review discusses the role of OPN and IL-17 in the development of MS and how the downregulation of the levels of OPN and interleukin-17 contributes to the therapeutic effects of IFN-&#x03B2; in MS.
Hong
Jian
J
Department of Neurology and Baylor Multiple Sclerosis Center, Baylor College of Medicine, Houston, Texas 77030, USA. jhong@bcm.tmc.edu
Hutton
George J
GJ
D015536:Down-Regulation / Q000187:drug effects; D006801:Humans; D016899:Interferon-beta / Q000276:immunology* / Q000494:pharmacology / Q000627:therapeutic use*; D020381:Interleukin-17 / Q000235:genetics* / Q000276:immunology; D009103:Multiple Sclerosis / Q000188:drug therapy* / Q000235:genetics* / Q000276:immunology; D053495:Osteopontin / Q000235:genetics* / Q000276:immunology
D020381:Interleukin-17; D053495:Osteopontin; D016899:Interferon-beta